1.
J Pain Symptom Manage
; 20(3): 210-3, 2000 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-11018339
RESUMO
The transdermal therapeutic system (TTS) fentanyl has been designed for rate-controlled drug delivery. When the system is applied, a fentanyl depot concentrates in the upper skin layers. Plasma concentrations are not measurable until 2 hours after application, and it takes an 8-16 hr latency period until full clinical fentany effects are observed. Following removal, serum fentanyl concentrations decline gradually and fall to about 50% in approximately 16 hours. We report the case of a 77-year-old man with a history of severe arthritis, who was receiving transdermal fentanyl and developed respiratory failure after starting epidural diamorphine/bupivacaine for postoperative pain relief following radical nephrectomy.
Assuntos
Analgésicos Opioides/efeitos adversos , Anestésicos Locais/efeitos adversos , Bupivacaína/efeitos adversos , Fentanila/efeitos adversos , Heroína/efeitos adversos , Nefrectomia , Cuidados Pós-Operatórios/efeitos adversos , Insuficiência Respiratória/induzido quimicamente , Administração Cutânea , Idoso , Humanos , Injeções Epidurais , Masculino
2.
Anaesthesia
; 54(5): 511, 1999 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-10995184